Brief: CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted For FDA Review
09/11/2020 13:41
Nov 9 (Reuters) - CNS Pharmaceuticals Inc CNSP.O :
* CNS PHARMACEUTICALS ANNOUNCES ADAPTIVE TRIAL DESIGN FOR
BERUBICIN PHASE 2 CLINICAL TRIAL TO BE SUBMITTED FOR FDA REVIEW
Source text for Eikon: ID:nPnbjccNda
Further company coverage: CNSP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CNS Pharmaceuticals
See all newsCNS Pharmaceuticals Q2 net loss widens, cash rises after financing
CNS Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Brief: Cns Pharmaceuticals Appoints Rami Levin As CEO Effective Jan 1, 2026